Methylphenidate-induced cytogenetic alterations?;Zytogenetische veränderungen durch methylphenidat?

Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie

Volumn 34, Issue 3, 2006, Pages 215-220

  Holtmann, Martin ^a   Kaina, Bernd ^b   Poustka, Fritz ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

ADHD; Carcinogenicity; Children; Methylphenidate; Mutagenicity

Indexed keywords

AMPHETAMINE; ATOMOXETINE; METHYLPHENIDATE;

BACTERIAL CELL; CANCER INCIDENCE; CARCINOGENIC ACTIVITY; CARCINOGENICITY; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOGENETICS; HUMAN; LIVER TUMOR; MAMMAL CELL; MICRONUCLEUS; MOUSE; MUTAGENIC ACTIVITY; MUTAGENICITY; NONHUMAN; RAT; REVIEW; SISTER CHROMATID EXCHANGE;

ADOLESCENT; ANIMALS; CARCINOGENICITY TESTS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; HUMANS; METHYLPHENIDATE; MICE; MUTAGENICITY TESTS; RATS; RISK;

EID: 33745055561     PISSN: 14224917     EISSN: None     Source Type: Journal    
DOI: 10.1024/1422-4917.34.3.215     Document Type: Review

References (23)

1. Bonassi, S., Znaor, A., Norppa, H. & Hagmar, L. (2004). Chromosomal aberrations and risk of cancer in humans: an epidemiologic perspective. Cytogenetic Genome Research, 104, 376-82.
2. Cantwell, D. P. (1996). Attention deficit disorder: a review of the past 10 years. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 978-987.
3. DGKJP (2003). Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter. Deutscher Ärzteverlag, Köln.
4. Drogenbeauftragte der Bundesregierung (2003). Drogen- und Suchtbericht 2003. Verfügbar unter: http://www.bmgs.bund. de/download/broschueren/ a601_2003.pdf.
5. Dunnick, J. K. & Hailey, J. R. (1995). Experimental studies on the long-term effects of methylphenidate hydrochloride. Toxicology, 103, 77-84.
6. Dunnick, J. K., Elwell, M. R. & Haseman, J. K. (1996). Decreased incidence of spontaneous mammary gland neoplasms in female F344 rats treated with amphetamine, methylphenidate, or codeine. Cancer Letters, 102, 77-83.
7. El-Zein, R. A., Abdel-Rahman, S. Z., Hay, M., Lopez, M., Bondy, M., Morris, D. L. & Legator, M. S. (2005). Cytogenetic effects in children treated with methylphenidate. Cancer Letters, 230, 284-291.
8. FDA (2005). Pediatric Advisory Committee - Cytogenetic effects of Methylphenidate. Verfügbar unter: www.fda.gov/ohrms/ dockets/ac/05/slides/ 20054152s2_03_Jacobsen%20Kram.ppt.
9. Galloway, S. M., Armstrong, M. J., Reuben, C., Colman, S., Brown, B., Cannon, C., Bloom, A. D., Nakamura, F., Ahmed, M., Duk, S. et al. (1987). Chromosome aberrations and sister chromatid exchanges in Chinese hamster ovary cells: evaluations of 108 chemicals. Environmental and molecular mutagenesis, 10, Suppl. 10, 1-175.
10. Gerlach, M., Banaschewski, T., Warnke, A. & Rothenberger, A. (2003). Ist ein Parkinson-Syndrom als Spätfolge einer Methylphenidat-Behandlung im Kindesalter möglich? Nervenheilkunde, 22, 80-84.
11. Huss, M. (2004). Langzeiteffekte der Stimulanzientherapie. In: M. Schulte-Markwort & A. Warnke (Hrsg.), Methylphenidat (S. 34-43). Stuttgart: Thieme.
12. International Programme on Chemical Safety (1985). Guidelines for the study of genetic effects in human populations. Environmental Health Criteria 46. Verfügbar unter: www.inchem. org/documents/ehc/ehc/ehc46.htm.
13. MTA Cooperative Group (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The Multimodal Treatment Study of Children with ADHD. Archives of General Psychiatry, 56, 1073-1086.
14. National Toxicology Program (1995). NTP Toxicology and Carcinogenesis Studies of Methylphenidate Hydrochloride (CAS No. 298-59-9) in F344/N Rats and B6C3F1 Mice (Feed Studies). National Toxicology Program Technical Report Series, 439, 1-299.
15. National Toxicology Program (2005). Center for the Evaluation of Risks to Human Reproduction - Expert Panel Report zu Methylphenidat. Verfügbar unter: http://cerhr.niehs.nih.gov/ news/stimulants/reports.html.
16. Obe, G. & Müller, W. U. (1999). Zytogenetik in der genetischen Toxikologie und Strahlenbiologie. Zeitschrift Medizinische Genetik, 11, 373-377.
17. Preston, R. J., Kollins, S. H., Swanson, J. M., Greenhill, L. L., Wigal, T., Elliott, G. R. & Vitiello, B. (2005). Comments on «Cytogenetic effects in children treated with methylphenidate» by El-Zein et al. Cancer Letters, 230, 292-294.
18. Teo, S. K., San, R. H., Wagner, V. O., Gudi, R., Stirling, D. I., Thomas, S. D. & Khetani, V. D. (2003). D-Methylphenidate is non-genotoxic in in vitro and in vivo assays. Mutation Research, 537, 67-79.
19. Selby, J., Friedman, G. & Fireman, B. (1989). Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Research, 49, 5737-5747.
20. Walitza, S., Herhaus, G., Melfsen, S., Scheuerpflug, P., Warnke, A. & Gerlach, M. (2004). Gibt es einen Zusammenhang zwischen ADHS und späterem Auftreten einer Parkinson-Erkrankung? - Ein Beitrag zur Methylphenidat-Debatte. Vortrag. XII. Wissenschaftliche Tagung Biologische Kinder- u. Jugendpsychiatrie. Göttingen. Abstractband: S.1.
21. Walker, A. P. & Dumars, K. W. (1977). Commonly used pediatric drugs, sister chromatid exchanges and the cell cycle. American Journal of Human Genetics, 29, 110 (abstract).
22. Warnke, A. & Walitza, S. (2004). Methylphenidat in der Behandlung der Aufmerksamkeits-Defizit-Hyperaktivitätsstörung (ADHS). In: M. Schulte-Markwort & A. Warnke (Hrsg.), Methylphenidat (S. 14-33). Stuttgart: Thieme.
23. Wilens, T. E., Faraone, S. V., Biederman, J. & Gunawardene, S. (2003). Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics, 111, 179-185.